Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, Iain will review a paper by B Fautrel, in which authors compare patient characteristics and long-term management with tocilizumab in RA patients over and under 75 years of age, and tolerance of RA treatments.

Join Doctor Sofia Ramiro and Professors Janet Pope and Atul Deodhar, as they review and discuss key data from ACR 2025 across RA, PsA, and axSpA, focusing on implications for clinical practice.

Join Doctor Sofia Ramiro as she summarises her top abstracts, posters, and presentations from Day 4 of ACR 2025 (Wednesdsy, 29th of October)

Join Doctor Sofia Ramiro as she summarises her top abstracts, posters, and presentations from Day 3 of ACR 2025 (Tuesday 28th of October)

Professors Janet Pope and John Isaacs discuss all the highlights from the 'Pathways Modulating IMIDs' webinar.

Join Doctor Sofia Ramiro as she summarises her top abstracts, posters, and presentations from Day 2 of ACR 2025 (Monday, 27th of October)

Join Doctor Sofia Ramiro as she summarises her top abstracts, posters, and presentations from Day 1 of ACR 2025 (Sunday, 26th of October)

Join Professors Peter Nash, Janet Pope and Atul Deodhar as they preview what they are most looking forward to this ACR, introducing some of the top chosen abstracts and posters in RA, AxSpA and PsA so that you can better plan your time at what will be a busy and exciting congress. #ACR2025

Join Professor Laura Coates and Phillip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered the ‘the effectiveness and safety of upadacitinib with secukinumab and adalimumab’ and ‘the efficacy of long-term treatment with risankizumab across the updated GRAPPA domains and key related conditions of PsA’.

Join Professor Peter Nash from the Griffith University in Brisbane, and Doctor David Kellner, an IGNITE-MSCR Fellow of the Division of Rheumatology, from UCLA Medical Centre, LA, USA, as they discuss his recent review ‘Effect of glucagon-like peptide 1 receptor agonists on patients with rheumatoid arthritis’.

Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he highlights two papers: risk of MACE, VTE, and malignancies in patients with RA or UC treated with filgotinib and frequency of reporting of MACE, MI, and stroke between JAKis and anti-TNFα.

Join Dr Sofia Ramiro and Professor Xenofon Baraliakos as they discuss the top publications in the world of axSpA. This month, the conversation covered the effectiveness of ixekizumab in real-world patients with axSpA and PsA, and the real‑world comparison of clinical effectiveness of UPA, TNF inhibitors or IL‑17 inhibitors in patients with axSpA after switching from an initial TNF inhibitor.

Join Professor Iain McInnes as he discusses the top publications in the world of RA. This month’s discussion covered the ‘Efficacy and safety of upadacitinib for patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis’. Read the full paper summary online at www.imidforum.com.

Join Professor Peter Nash from Griffith University in Brisbane, and Dr Rodrigo Garcia‑Salinas from Hospital Italiano de La Plata in Argentina, as they discuss Dr Garcia-Salinas’ recent publication ‘Difficult-to-Manage Axial Spondyloarthritis According to ASAS Criteria in Reuma-Check Cohort: Frequency, Predictive Factors, and Treatment Patterns’.

Join Professor Peter Nash from the Griffith University in Brisbane, and authors Dr Martin Schaefer from the German Rheumatology Research Center in Berlin, Germany and Professor Anja Strangfeld, the head of epidemiology at the German Rheumatology Research Centre. In this episode they discuss a recent study from the German RABBIT registry, investigating the comparative risk of malignancies in rheumatoid arthritis patients treated with JAK inhibitors versus bDMARDs.

Join Professor Laura Coates and Phillip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered the ‘the influence of csDMARDs use on efficacy and safety of deucravacitinib in pateints with PsA’ and ‘the incidence rate of uveitis in patients with axSpA and PsA treated with secukinumab’.

Join Professor Iain McInnes as he discusses the top publications in the world of RA. This month, the conversation covered the ‘dual JAK and ROCK inhibition with CPL’116 in patients with RA with inadequate response to MTX’ and ‘the benefit–risk analysis of UPA versus adalimumab in patients with RA and higher or lower risk of cardiovascular disease’

Join Dr Sofia Ramiro and Professor Xenofon Baraliakos as they discuss the top publications in the world of axSpA. This month, the conversation covered treatment outcomes in European real-world patients with axSpA and PsA, treated with secukinumab and the effects of secukinumab on skeletal microarchitecture and vertebral fractures in patients with axSpA.

Join Professor Iain McInnes from the University of Glasgow, and Professor Peter Nash from the Griffith University in Brisbane, as they discuss the concept of difficult-to-treat disease in rheumatology.

Join Professors Xenofon Baraliakos, Laura Coates, and Johannes Bijlsma as they review their highlights of the recent EULAR 2025 congress, and watch them discuss the key abstracts and information.